tradingkey.logo
tradingkey.logo

Gyre Therapeutics Announces China’S Nmpa Grants Priority Review To The NDA For Hydronidone (F351) For Chb-Induced Liver Fibrosis Treatment

ReutersMar 17, 2026 11:51 AM

- Gyre Therapeutics Inc GYRE.O:

  • GYRE THERAPEUTICS ANNOUNCES CHINA’S NMPA GRANTS PRIORITY REVIEW TO THE NDA FOR HYDRONIDONE (F351) FOR CHB-INDUCED LIVER FIBROSIS TREATMENT

  • GYRE THERAPEUTICS INC - CO THROUGH UNIT PANS FORMAL NDA SUBMISSION FOR HYDRONIDONE IN NEAR FUTURE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI